-43.7%
BABA vs MRNA
+786.4%
-830.1%
-80.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.7% | -2.2% | -0.5% | -2.6% |
| 7D | -14.1% | -12.7% | -1.4% | -13.4% |
| 30D | -22.3% | -20.7% | -1.7% | -21.5% |
| 3M | -37.9% | +46.3% | -84.1% | -39.4% |
| 6M | -39.2% | +305.2% | -344.4% | -47.4% |
| YTD | -44.2% | +561.2% | -605.4% | -54.4% |
| 1Y | -46.6% | +772.1% | -818.7% | -57.7% |
| 3Y | +9.8% | +147.0% | -137.1% | -5.0% |
| 5Y | -38.6% | -26.1% | -12.5% | -43.8% |
| All | -43.7% | +786.4% | -830.1% | -54.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling